<![CDATA[Nogapendekin Alfa/BCG Shows 84% Cystectomy-Free Survival at 3 Years]]>

Data Readoutpositivenogapendekin alfa inbakiceptPositive

AI Analysis

Summary

Long-term QUILT-3.032 data showed nogapendekin alfa inbakicept plus BCG achieved a 71% complete response rate with a median duration of 26.6 months in BCG-unresponsive NMIBC. Cystectomy-free survival was 84% at 3 years.

Clinical Trial Data

Phase

Phase_2

Outcome Details

Long-term QUILT-3.032 data showed a 71% complete response rate with a median duration of 26.6 months and 84% cystectomy-free survival at 3 years with nogapendekin alfa inbakicept plus BCG in BCG-unresponsive NMIBC.

Importance:5/10

Sentiment:

0.70

NMIBCbladder cancerBCG-unresponsivelong-term dataQUILT-3.032immunotherapycomplete responsecystectomy-free survival

Related Companies

$ALMDT.PA

Read the original article

Published by Cancer Network on October 19, 2026 3:00 PM

Read Original